Anders Gabrielsen

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 8

Top Topics

Acute Coronary Syndrome

Induced Pluripotent Stem Cells

Placebo Controlled

Top Venues

Journal of the American Heart Association

This page only lists publications with an associated author ORCID identifier.

Publications

Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Kathleen Connolly, Richard T George, Sami Omar, Elin Matsson, Magnus Åstrand, Magnus Althage, Daniel Pettersen, Esha Mohamed, Kelly Fang, Joao Augusto Costa Lima, Mirjana Kujacic, Helena Ödesjö, Michelle Turton, Petra Johannesson, Anders Gabrielsen, Marcin Ufnal
Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study. Journal of the American Heart Association 13 (15) (2024)
Kathleen Connolly, Richard T George, Sami Omar, Elin Matsson, Magnus Åstrand, Magnus Althage, Daniel Pettersen, Esha Mohamed, Kelly Fang, Joao Augusto Costa Lima, Mirjana Kujacic, Helena Ödesjö, Michelle Turton, Petra Johannesson, Anders Gabrielsen, Marcin Ufnal
Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study. Journal of the American Heart Association (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)
Dimitris Kardassis, Ann-Charlotte Egnell, Magnus Åstrand, Samuel J Daniels, Carl Whatling, Ola Fjellström, Anders Gabrielsen
Safety, Tolerability, and Pharmacodynamics of AZD3366 (Optimized Human CD39L3 Apyrase) Alone and in Combination With Ticagrelor and Acetylsalicylic Acid: A Phase 1, Randomized, Placebo-Controlled Study. Journal of the American Heart Association 13 (11) (2024)